Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
US Department of Justice
Farmers Insurance
Julphar
Moodys
Colorcon
Federal Trade Commission
Cipla
Harvard Business School

Generated: January 19, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,338,427

« Back to Dashboard

Summary for Patent: 8,338,427
Title:Methods for administering aripiprazole
Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
Inventor(s): Brown; Josiah (Seattle, WA)
Assignee: Alkermes, Inc. (Waltham, MA)
Application Number:12/251,656
Patent Claims: 1. An injectable composition that is free of sustained release materials for the extended release of aripiprazole comprising a suspension of at least about 10 mg/ml of aripiprazole in an injection vehicle optionally comprising a viscosity enhancing agent and wherein the aripiprazole release is for at least 7 days.

2. The composition of claim 1, wherein the viscosity enhancing agent comprises carboxymethyl cellulose.

3. The composition of claim 1, wherein said injection vehicle further comprises a wetting agent.

4. The composition of claim 3, wherein the wetting agent is selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 80.

5. The composition of claim 1, wherein said injection vehicle comprises a density enhancing agent.

6. The composition of claim 5, wherein said density enhancing agent comprises sorbitol.

7. The composition of claim 1, wherein said injection vehicle comprises a tonicity adjusting agent.

8. The composition of claim 7, wherein said tonicity adjusting agent comprises sodium chloride.

9. A composition comprising a suspension of at least about 10 mg of aripiprazole and an aqueous injection vehicle comprising water, a viscosity enhancing agent, a wetting agent and a tonicity agent wherein upon administration of the composition the aripiprazole release is for at least 7 days.

10. A composition comprising a suspension of at least about 10 mg of aripiprazole and an aqueous injection vehicle comprising water, about 3% by volume carboxymethylcellulose, about 0.1% polysorbate 20 and about 0.9% by weight to about 1% by weight sodium chloride wherein upon administration of the composition the aripiprazole release is for at least 7 days.

11. A method for providing aripiprazole to an individual in an extended release injectable composition that is free of sustained release materials comprising administering a mixture of at least about 10 mg/ml of aripiprazole in an injection vehicle optionally comprising a viscosity enhancing agent and wherein a therapeutically effective amount of the aripiprazole is present in the plasma of the individual for at least about 7 days.

12. The method of claim 11, wherein the viscosity enhancing agent comprises carboxymethyl cellulose.

13. The method of claim 11, wherein the injection vehicle further comprises a wetting agent.

14. The method of claim 13, wherein the wetting agent is selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 80.

15. The method of claim 11, wherein said injection vehicle comprises a density enhancing agent.

16. The method of claim 15, wherein said density enhancing agent comprises sorbitol.

17. The method of claim 11, wherein said injection vehicle comprises a tonicity adjusting agent.

18. The method of claim 17, wherein said tonicity adjusting agent comprises sodium chloride.

19. The method of claim 11, wherein the composition is administered by injection selected from the group consisting of: intramuscular injection or subcutaneous injection.

20. The method of claim 11 further comprising a second administration of the composition selected from the group consisting of: at least about 7 days after first administration and at least about 14 days after the first administration.

21. A method for providing aripiprazole to an individual in an extended release injectable composition comprising administering a composition of claim 10.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Farmers Insurance
US Department of Justice
AstraZeneca
UBS
Mallinckrodt
Chubb
Boehringer Ingelheim
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot